Immunic, Inc. (NASDAQ:IMUX) Stock Has Average Price Target of $35.43 According to Brokerages

Key Points

• Analysts remain broadly optimistic: Twelve brokerages give Immunic an average “Buy” rating, with an average 12-month price target of $35.43. Ratings include seven buys, three strong buys, one hold, and one sell.
• Institutional ownership increased: Several funds recently purchased or expanded their positions, and institutional investors now own 51.82% of Immunic’s stock.
• Shares have fallen sharply: IMUX opened at $7.56, well below its 12-month high of $17.43. The company reported a quarterly loss of $0.80 per share, beating the consensus estimate of a $1.16 loss, while analysts expect a full-year loss of $3.71 per share.

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has received an average recommendation of "Buy" from the twelve analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $35.43.

A number of research analysts have recently issued reports on IMUX shares. Wedbush reissued an "outperform" rating and issued a $45.00 price objective on shares of Immunic in a research note on Thursday, September 10th. Wall Street Zen raised Immunic from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Roth Capital reiterated a "buy" rating on shares of Immunic in a report on Tuesday, September 1st. HC Wainwright reissued a "buy" rating and issued a $22.00 price target on shares of Immunic in a research note on Thursday, September 10th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Immunic in a report on Wednesday, August 26th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IMUX. Braidwell LP bought a new position in shares of Immunic during the 2nd quarter worth about $9,914,000. Avidity Partners Management LP grew its stake in shares of Immunic by 42.6% in the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company's stock valued at $7,436,000 after buying an additional 2,000,000 shares during the period. CTC Alternative Strategies Ltd. bought a new stake in Immunic in the 1st quarter valued at about $27,000. Bank of America Corp DE boosted its holdings in Immunic by 80,724.2% in the first quarter. Bank of America Corp DE now owns 143,867 shares of the company's stock worth $160,000 after acquiring an additional 143,689 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in Immunic in the first quarter valued at approximately $33,000. 51.82% of the stock is owned by institutional investors.

Immunic Stock Down 0.9%

IMUX opened at $7.56 on Friday. Immunic has a twelve month low of $5.06 and a twelve month high of $17.43. The company has a fifty day moving average of $12.71 and a 200-day moving average of $12.83. The stock has a market cap of $103.12 million, a PE ratio of -1.73 and a beta of 1.45.

Immunic (NASDAQ:IMUX - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.36. Sell-side analysts anticipate that Immunic will post -3.71 EPS for the current fiscal year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic's lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.